Sentry Investments Corp. bought a new position in Johnson & Johnson (NYSE:JNJ) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 86,300 shares of the company’s stock, valued at approximately $11,417,000.
A number of other hedge funds have also added to or reduced their stakes in the business. Lenox Wealth Advisors Inc. increased its stake in Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the period. Premier Asset Management LLC increased its stake in Johnson & Johnson by 0.4% in the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after purchasing an additional 12 shares during the period. Lbmc Investment Advisors LLC increased its stake in Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock worth $492,000 after purchasing an additional 14 shares during the period. Halbert Hargrove Russell LLC increased its stake in Johnson & Johnson by 0.4% in the second quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock worth $466,000 after purchasing an additional 15 shares during the period. Finally, Stratford Consulting LLC increased its stake in Johnson & Johnson by 0.6% in the second quarter. Stratford Consulting LLC now owns 2,728 shares of the company’s stock worth $361,000 after purchasing an additional 16 shares during the period. Institutional investors and hedge funds own 65.90% of the company’s stock.
JNJ has been the topic of a number of recent analyst reports. Goldman Sachs Group lowered Johnson & Johnson from a “neutral” rating to a “sell” rating and increased their target price for the stock from $125.00 to $130.00 in a research note on Wednesday, September 20th. BMO Capital Markets restated a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a research note on Friday, September 1st. Vetr upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price target on the stock in a research note on Monday, October 30th. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the company an “outperform” rating in a research note on Thursday, October 19th. Finally, UBS restated an “underweight” rating on shares of Johnson & Johnson in a research note on Thursday, August 24th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $144.59.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same quarter last year, the company earned $1.68 earnings per share. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. sell-side analysts predict that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.38%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s payout ratio is currently 58.33%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.